6533b7d0fe1ef96bd125b931

RESEARCH PRODUCT

Evolution of Therapy Decision-Making Process for Advanced Non-Small Cell Lung Cancer

Lucia LombardiEvaristo MaielloGianfranco MancusoVittorio Gebbia

subject

OncologyCancer Researchmedicine.medical_specialtyPoor prognosisLung Neoplasmsmedicine.medical_treatmentDecision MakingAntineoplastic AgentsDiseaseCarcinoma Non-Small-Cell LungInternal medicineBiomarkers TumormedicineHumansLung cancerChemotherapybusiness.industryRespiratory diseaseCancerGeneral Medicinemedicine.diseaseTreatment OutcomeOncologyPharmacogeneticsPharmacogenomicsImmunologyNon small cellbusiness

description

Advanced non-small cell lung cancer remains a lethal disease with poor prognosis. In the last decades results of systemic chemotherapy have reached a disappointing plateau without significant differences between the most widely employed third-generation regimens. Recent scientific evidence has shed new light on the management of advanced non-small cell lung cancer, especially for the important role of histological definition in therapy-planning process. The results of new biologic agents are also reported as are the promising data on pharmacogenomic-guided treatment.

yearjournalcountryeditionlanguage
2010-02-05Oncology
https://doi.org/10.1159/000258501